Every 10-Q that AirSculpt Technologies, Inc. (AIRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIRS filings page.
AirSculpt Technologies, Inc. reported modestly lower activity and continued losses for the three and six months ended June 30, 2026. Revenue was $42.9 million for the quarter and $82.3 million year‑to‑date, down slightly from the prior‑year periods as cases were essentially flat while revenue per case declined. Q2 net loss was $1.1 million and first‑half net loss was $3.5 million, or $(0.02) and $(0.05) per share, respectively. Adjusted EBITDA remained positive at $4.9 million in Q2 and $8.2 million for the first half, but margins compressed.
The company ended June 30, 2026 with $18.8 million of cash and $43.6 million of term debt (net), after voluntary prepayments and equity raises via an at‑the‑market program that generated $19.6 million in first‑half net proceeds. Interest expense declined as debt was reduced, while advertising expense and customer acquisition costs increased, pressuring profitability. A Fourth Amendment to the credit agreement subsequently extended maturities to November 15, 2027 and added mandatory prepayments and enhanced lender reporting.
Management continues to report material weaknesses in internal control over financial reporting, including general accounting processes and lease accounting under ASC 842; remediation efforts are underway but not yet completed.
AirSculpt Technologies, Inc. reported essentially flat performance for the three months ended March 31, 2026, generating revenue of $39.4 million on 3,082 cases, similar to $39.4 million and 3,076 cases a year earlier. Revenue per case was stable at about $12,780.
The company posted a net loss of $2.4 million, modestly better than the $2.8 million loss in 2025, while Adjusted EBITDA declined to $3.3 million, an 8.4% margin versus 9.5% a year ago, reflecting higher selling, general and administrative costs.
AirSculpt strengthened its balance sheet by raising approximately $14.6 million through its at-the-market equity program and voluntarily prepaying $10.0 million on its term loan, reducing total debt, net, to $44.8 million. Cash and cash equivalents increased to $16.7 million, and management concluded there is no substantial doubt about the company’s ability to continue as a going concern. However, previously disclosed material weaknesses in internal control over financial reporting, including general accounting processes and lease accounting under ASC 842, remained unremediated as of March 31, 2026.
AirSculpt Technologies (AIRS) reported weaker Q3 2025 results. Revenue was $34.99 million, down about 18% year over year as procedure volumes and demand across the aesthetics industry softened. The company posted a net loss of $9.51 million (basic and diluted loss per share of $0.15) versus a $6.04 million loss a year ago.
Results included non-cash charges: a $4.6 million impairment tied to portions of a Salesforce implementation and a $2.3 million impairment from the planned closure of the London facility. Management also accelerated $1.0 million of rent expense related to ceasing use of the London lease on November 15, 2025. Same-center cases fell 20.5% with revenue per case modestly lower.
Cash was $5.41 million at quarter-end, and term debt (net) was $56.91 million at an 8.82% interest rate. During Q2, AirSculpt raised approximately $13.8 million net in an underwritten offering and prepaid $10.0 million on the term loan, while amending covenants to provide near-term flexibility. Management is executing cost reductions estimated at $3.0 million annually and has paused new center openings.
AirSculpt Technologies (AIRS) Q2-25 10-Q highlights:
- Revenue: $44.0 m, -14% YoY; H1-25 revenue $83.4 m, -15% YoY.
- Case volume: 3,392 for the quarter (-14%); revenue per case stable at ~$12.9k.
- Profitability: Adj. EBITDA $5.8 m (13.3% margin vs. 13.5% LY); GAAP net loss $(0.6) m vs. $(3.2) m LY. H1 net loss $(3.4) m.
- Cost actions: Advertising down $3.7 m; $3 m annual overhead cuts; de-novo expansion paused.
- Capital & liquidity: Cash $8.2 m; term-loan $58.8 m (rate 7.8%); leverage covenant amended in Mar-25; $10 m debt pre-payment on 13-Jun-25 funded by $14 m follow-on equity offering (3.6 m shares at $3.80).
- ATM program: 0.12 m shares sold YTD for $0.3 m.
- Balance sheet: Total assets $198.4 m; stockholders’ equity $91.2 m; net debt ~$50.6 m.
- Guidance/strategy: Management focusing on marketing ROI, sales training, new financing options, product innovation and standalone skin-tightening; aims to stabilize same-center performance amid industry softness.
Key risks include declining demand, leverage (LT debt/Adj. EBITDA ≈ 5.0x), tighter covenants, and rising interest margin from July 2025.